眼科主业遇瓶颈，爱博医疗6.83亿元跨界运动医学

Core Viewpoint - Aibo Medical is seeking new growth opportunities after experiencing its first decline in net profit for the first three quarters since its IPO, announcing plans to acquire a 68.31% stake in Demai Medical for 683 million yuan [2][5][6] Group 1: Acquisition Details - The acquisition will be financed through a combination of acquisition loans and the company's own funds, with Demai Medical becoming a subsidiary and included in Aibo Medical's consolidated financial statements [5][6] - Demai Medical, a leading company in sports medicine, generates approximately 80% of its revenue from sports medicine implants, surgical tools, and rehabilitation equipment [5][6] - The acquisition includes performance guarantees, with Demai Medical's founders committing to achieve audited net profits of at least 45 million yuan, 55 million yuan, and 65 million yuan for the years 2026 to 2028, or a cumulative net profit of no less than 165 million yuan during the same period [6][7] Group 2: Financial Performance and Challenges - Aibo Medical's net profit for the first three quarters of 2025 decreased by 8.64% year-on-year, marking the first decline since its IPO, with total revenue of 1.144 billion yuan, a slight increase of 6.43% [7][8] - The decline in profit is attributed to challenges in its core businesses, particularly in artificial lenses and contact lenses, which have seen reduced revenue and increased competition [8][9] - The artificial lens business, which previously contributed over 80% of revenue, is facing a pricing pressure due to policy changes, while the contact lens segment, despite significant revenue growth, suffers from low profit margins [8][9] Group 3: Strategic Shift and Market Context - The acquisition of Demai Medical represents Aibo Medical's strategic shift to diversify its business and seek new growth avenues in the sports medicine sector, which is experiencing rapid growth and has significant potential for domestic alternatives [9][10] - The move is seen as a response to the pressures faced by Aibo Medical's core ophthalmic business, similar to other companies in the industry that are also pursuing acquisitions to expand their product offerings [9][10] - However, the integration of the two businesses poses challenges due to differing target markets and potential financial pressures from the acquisition [10]